Value
6.8/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 9.7 |
| Fwd P/E | 1.0 |
| PEG | 4.7 |
| Analyst target | 9.0 |
- ▸Forward P/E: 193.1x
- ▸PEG: 1.83
TNDM · Why this verdict
Why Tandem Diabetes Care (TNDM) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Tandem Diabetes Care offers 56.8% analyst-implied upside with three of the last four quarters showing earnings beats and improving EPS surprises, but a quality score of 3.1 below the investment floor, 23% short interest, and a single critical supplier dependency on Unomedical make this a high-risk setup.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analyst consensus implies 56.8% upside from the current price of $16.76 to a target of $26.28, and analyst upside of 74% reflects strong buy-side confidence in the recovery trajectory of Tandem's insulin pump business as the company works toward profitability. Targets | Price rises above $22 within 12 months, closing more than 55% of the gap toward the analyst target of $26.28. | →Stable |
| CounterThe stock is near its 52-week low and high analyst upside targets for cash-burning medical device companies often reflect aspirational scenario analysis rather than near-term fundamental catalysts. | ||
Three of the last four quarters showed earnings beats with improving positive surprises of 33%, 89%, and 9%, and the average surprise of 26.9% over the past year indicates the company is increasingly beating the cost and revenue expectations embedded in analyst models. Earnings | Beat count reaches at least 3 of the next 4 quarters and average surprise percentage remains above 15%. | →Stable |
| CounterThe one miss quarter showed a -22.4% negative surprise, and all beats are against negative EPS estimates, meaning the company is losing less money than expected rather than achieving profitability. | ||
The quality score of 3.1 falls below the minimum investment threshold of 4.0, the company is cash-flow negative at -2% of revenue, and return on equity and return on assets are both zero — indicating the business has not yet demonstrated the financial self-sustainability required for investment consideration. Warnings | Quality score rises above 4.0 and free cash flow turns positive on a trailing twelve-month basis within 12 months. | →Stable |
| CounterA current ratio of 9.4 means the company has ample near-term liquidity, and a cash burn rate of only -2% of revenue is relatively modest for a medical device company at this stage of commercialization. | ||
A single-supplier concentration risk in Unomedical A/S — flagged as a high-severity concentration risk in the 10-K — combined with 23% short interest and a put/call ratio of 1.47 indicate that both supply chain fragility and market bearishness are meaningful headwinds. Bear case | Short interest falls below 15%, declining more than 35% from the current 23% level, as the company demonstrates supply chain resilience and earnings improvement. | →Stable |
| CounterHigh short interest of 23% creates a significant short-squeeze potential — if a positive catalyst materializes, short covering could amplify upside well beyond the analyst target of $26.28. | ||
Analyst consensus implies 56.8% upside from the current price of $16.76 to a target of $26.28, and analyst upside of 74% reflects strong buy-side confidence in the recovery trajectory of Tandem's insulin pump business as the company works toward profitability.
→StableTargets
- Expectation
- Price rises above $22 within 12 months, closing more than 55% of the gap toward the analyst target of $26.28.
CounterThe stock is near its 52-week low and high analyst upside targets for cash-burning medical device companies often reflect aspirational scenario analysis rather than near-term fundamental catalysts.
Three of the last four quarters showed earnings beats with improving positive surprises of 33%, 89%, and 9%, and the average surprise of 26.9% over the past year indicates the company is increasingly beating the cost and revenue expectations embedded in analyst models.
→StableEarnings
- Expectation
- Beat count reaches at least 3 of the next 4 quarters and average surprise percentage remains above 15%.
CounterThe one miss quarter showed a -22.4% negative surprise, and all beats are against negative EPS estimates, meaning the company is losing less money than expected rather than achieving profitability.
The quality score of 3.1 falls below the minimum investment threshold of 4.0, the company is cash-flow negative at -2% of revenue, and return on equity and return on assets are both zero — indicating the business has not yet demonstrated the financial self-sustainability required for investment consideration.
→StableWarnings
- Expectation
- Quality score rises above 4.0 and free cash flow turns positive on a trailing twelve-month basis within 12 months.
CounterA current ratio of 9.4 means the company has ample near-term liquidity, and a cash burn rate of only -2% of revenue is relatively modest for a medical device company at this stage of commercialization.
A single-supplier concentration risk in Unomedical A/S — flagged as a high-severity concentration risk in the 10-K — combined with 23% short interest and a put/call ratio of 1.47 indicate that both supply chain fragility and market bearishness are meaningful headwinds.
→StableBear case
- Expectation
- Short interest falls below 15%, declining more than 35% from the current 23% level, as the company demonstrates supply chain resilience and earnings improvement.
CounterHigh short interest of 23% creates a significant short-squeeze potential — if a positive catalyst materializes, short covering could amplify upside well beyond the analyst target of $26.28.
Per-dimension breakdown
Quality
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 7.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.4 |
| FCF quality | 0.0 |
| Moat | 5.1 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -2% of revenue
- ▸No competitive moat
Growth
7.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 3.9 |
| EPS growth | 10.0 |
Momentum
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 0.9 |
| OBV | 10.0 |
| MA position | 2.2 |
| Volume | 0.0 |
- ▸Capitulation risk (RSI 29, below 200MA)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+2.7%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 7.5 |
| Price target | 9.9 |
- ▸Analyst upside: 87%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.5 |
| quality rank | 1.1 |
| growth rank | 3.8 |
Technical
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.6 |
| support resistance | 7.1 |
| 52w position | 0.7 |
Risk (lower is worse)
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.2 |
| days to cover | 6.8 |
| volatility | 0.0 |
| put call | 4.7 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 4.8 |
| debt equity | 0.0 |
| news risk | 6.0 |
- ▸High short interest justified: 23%
- ▸High IV: 88%
- ▸Above max pain $3
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 7.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (5)
- ASYMMETRY:4.9>=1.5
- INSIDER:OK
- EARNINGS_PROXIMITY:41d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.2<4.5
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
4.91
Upside
+67.9%
Downside
13.8%
Sizing output
AVOID
SetupFALLING_KNIFE — Death cross, below all MAs, RSI 29, MACD bearish
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 1.57>1.3, MCap $1.0B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 7.9 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:3.2<4.5.
The strongest dimensions are Sentiment at 7.9, Growth at 7.0, and Value at 6.8; the weakest are Risk (lower is worse) at 2.9, Quality at 3.1, and Momentum at 3.2. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 4.91 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analyst consensus implies 56.8% upside from the current price of $16.76 to a target of $26.28, and analyst upside of 74% reflects strong buy-side confidence in the recovery trajectory of Tandem's insulin pump business as the company works toward profitability.
Trip ifAnalyst consensus price target falls below $18, more than 31% below the current target of $26.28, signaling a significant downgrade to the recovery case.
- P2Three of the last four quarters showed earnings beats with improving positive surprises of 33%, 89%, and 9%, and the average surprise of 26.9% over the past year indicates the company is increasingly beating the cost and revenue expectations embedded in analyst models.
Trip ifEPS surprise falls below -30% in at least 2 of the next 4 quarters, confirming that the improving beat pattern has reversed.
- P3The quality score of 3.1 falls below the minimum investment threshold of 4.0, the company is cash-flow negative at -2% of revenue, and return on equity and return on assets are both zero — indicating the business has not yet demonstrated the financial self-sustainability required for investment consideration.
Trip ifCash burn rate increases to greater than -10% of revenue, more than 5 times worse than the current -2% level, signaling accelerating capital consumption.
- P4A single-supplier concentration risk in Unomedical A/S — flagged as a high-severity concentration risk in the 10-K — combined with 23% short interest and a put/call ratio of 1.47 indicate that both supply chain fragility and market bearishness are meaningful headwinds.
Trip ifShort interest rises above 30%, exceeding the already elevated 23% by more than 7 percentage points, confirming that bearish conviction is intensifying.